Beam Therapeutics Management
Management criteria checks 4/4
Beam Therapeutics' CEO is John Evans, appointed in Apr 2017, has a tenure of 7.08 years. total yearly compensation is $6.28M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 1.25% of the company’s shares, worth $22.02M. The average tenure of the management team and the board of directors is 4.5 years and 4.6 years respectively.
Key information
John Evans
Chief executive officer
US$6.3m
Total compensation
CEO salary percentage | 10.9% |
CEO tenure | 7.1yrs |
CEO ownership | 1.3% |
Management average tenure | 4.5yrs |
Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$135m |
Dec 31 2023 | US$6m | US$685k | -US$133m |
Sep 30 2023 | n/a | n/a | -US$314m |
Jun 30 2023 | n/a | n/a | -US$327m |
Mar 31 2023 | n/a | n/a | -US$316m |
Dec 31 2022 | US$9m | US$650k | -US$289m |
Sep 30 2022 | n/a | n/a | -US$315m |
Jun 30 2022 | n/a | n/a | -US$234m |
Mar 31 2022 | n/a | n/a | -US$238m |
Dec 31 2021 | US$14m | US$590k | -US$371m |
Sep 30 2021 | n/a | n/a | -US$401m |
Jun 30 2021 | n/a | n/a | -US$408m |
Mar 31 2021 | n/a | n/a | -US$366m |
Dec 31 2020 | US$907k | US$529k | -US$196m |
Sep 30 2020 | n/a | n/a | -US$132m |
Jun 30 2020 | n/a | n/a | -US$119m |
Mar 31 2020 | n/a | n/a | -US$106m |
Dec 31 2019 | US$2m | US$473k | -US$91m |
Sep 30 2019 | n/a | n/a | -US$86m |
Jun 30 2019 | n/a | n/a | -US$134m |
Mar 31 2019 | n/a | n/a | -US$124m |
Dec 31 2018 | US$4m | US$441k | -US$117m |
Compensation vs Market: John's total compensation ($USD6.28M) is about average for companies of similar size in the US market ($USD5.66M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Evans (45 yo)
7.1yrs
Tenure
US$6,280,099
Compensation
Mr. John M. Evans, MBA, served as a Director at Prime Medicine, Inc until September 13, 2022. He serves as Chief Executive Officer and Director at Beam Therapeutics Inc. since January 2018 and served as it...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 7.1yrs | US$6.28m | 1.25% $ 22.0m | |
President | 4.3yrs | US$2.79m | 0.13% $ 2.3m | |
CFO & Treasurer | 4.8yrs | US$2.56m | 0.020% $ 348.5k | |
Senior VP | 5.1yrs | US$2.28m | 0.054% $ 939.8k | |
Chief Medical Officer | 3.2yrs | US$2.55m | 0.0017% $ 30.4k | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Co-Founder | no data | no data | no data | |
Chief Technology Officer | no data | no data | no data | |
Chief Scientific Officer | 1.2yrs | no data | no data |
4.5yrs
Average Tenure
54yo
Average Age
Experienced Management: BEAM's management team is considered experienced (4.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | no data | US$6.28m | 1.25% $ 22.0m | |
Independent Director | 2.5yrs | US$435.22k | 0% $ 0 | |
Independent Director | 6yrs | US$465.22k | 0.021% $ 375.9k | |
Independent Director | 6.9yrs | US$445.22k | 0.024% $ 418.7k | |
Independent Director | 4.6yrs | US$450.22k | 0% $ 0 | |
Independent Director | 3.3yrs | US$447.72k | 0% $ 0 | |
Independent Director | less than a year | US$772.68k | no data | |
Independent Director | 5.5yrs | US$442.72k | 0% $ 0 |
4.6yrs
Average Tenure
54.5yo
Average Age
Experienced Board: BEAM's board of directors are considered experienced (4.6 years average tenure).